Vestipitant

Vestipitant (INN)[1]^:98 is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK₁ receptor. It is under development as a potential antiemetic and anxiolytic drug,[2][3] and as a treatment for tinnitus[4] and insomnia.[5]

Vestipitant

Clinical data
ATC code	None
Identifiers
IUPAC name (2S)-N-{(1R)-1-[3,5-bis(trifluoromethyl) phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methylpiperazine-1-carboxamide
CAS Number	334476-64-1^Y
PubChem CID	9832383
IUPHAR/BPS	5757
ChemSpider	8008111^N
UNII	S052TOI9BI
KEGG	D06293^N
ChEMBL	ChEMBL522987^N
CompTox Dashboard (EPA)	DTXSID50187092
Chemical and physical data
Formula	C23H21F10N3O
Molar mass	545.425 g·mol^−1
3D model (JSmol)	Interactive image
SMILES FC(F)(F)c1cc(F)ccc1C2CNCCN2C(=O)N(C)C(C)c3cc(C(F)(F)F)cc(c3)C(F)(F)F
InChI InChI=1S/C23H24F7N3O/c1-13-8-18(24)4-5-19(13)20-12-31-6-7-33(20)21(34)32(3)14(2)15-9-16(22(25,26)27)11-17(10-15)23(28,29)30/h4-5,8-11,14,20,31H,6-7,12H2,1-3H3/t14-,20-/m1/s1^N Key:SBBYBXSFWOLDDG-JLTOFOAXSA-N^N
^NY (what is this?)  (verify)

See also

• NK₁ receptor antagonist
• Aprepitant
• Casopitant
• Fosaprepitant
• L-733,060
• Maropitant

References

1. "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 53" (PDF). World Health Organization. Retrieved 17 November 2016.
2. Reddy GK, Gralla RJ, Hesketh PJ (April 2006). "Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis". Supportive Cancer Therapy. 3 (3): 140–2. doi:10.3816/SCT.2006.n.011. PMID 18632487.
3. Brocco M, Dekeyne A, Mannoury la Cour C, Touzard M, Girardon S, Veiga S, et al. (October 2008). "Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents". European Neuropsychopharmacology. 18 (10): 729–50. doi:10.1016/j.euroneuro.2008.06.002. PMID 18657401.
4. Clinical trial number NCT00394056 for "Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss" at ClinicalTrials.gov
5. Ratti E, Carpenter DJ, Zamuner S, Fernandes S, Squassante L, Danker-Hopfe H, et al. (December 2013). "Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia". Sleep. 36 (12): 1823–30. doi:10.5665/sleep.3208. PMC 3825431. PMID 24293756.